Abstract
BackgroundThere is a paucity of data on long term clinical effects of high frequency chest wall oscillation (HFCWO) in the Bronchiectasis population. Other therapies such as nebulized mucolytics and long term antibiotics have proven benefit on quality of life and exacerbation rate. In this study a treatment algorithm that included HFCWO as a component was initiated to see what the long term effects of the proposed algorithm were on lung function, antibiotic use, and exacerbation rates.MethodsThis was an observational comparative retrospective cohort study from database of patients with Bronchiectasis. Patients with > 2 exacerbations and significant symptom burden were enrolled to receive a treatment algorithm. The algorithm included: nebulized bronchodilators, mucolytics (hypertonic saline (3–7%) or n-acetylcysteine) inhaled daily or twice daily, thrice weekly macrolide therapy when appropriate, and high frequency chest wall oscillation (HFCWO) therapy (daily to twice daily per issued protocol) Outcomes from the cohort were analyzed for the subsequent twelve months after initiation to observe longitudinal lung function and clinical outcomes. Chart review was then done to obtain data the year prior to the start of the algorithm in this same cohort of patients.ResultsSixty-five patients received the Smart Vest® HFCWO system and were enrolled into the algorithm for treatment during the study period. Of the sixty-five patients, forty-three were eligible due to adequate 1-year baseline and follow up data at the time of the study initiation. The mean FEV1 remained stable at 1-year post enrollment (1.85 ± 0.60 L pre vs 1.89 ± 0.60 L post, p = NS) and the number of exacerbations requiring hospitalization was reduced (1.3 ± 1.0 pre vs. 0.46 ± 0.81 hospitalizations, post initiation, p < 0.0001). Antibiotic use overall was also reduced (2.5 ± 0.86 courses/year pre vs 2.1 ± 0.92 courses per year post initiation, p < 0.0001).ConclusionStandardized care for Bronchiectasis involving an algorithm for Mucociliary clearance that centers on initiation of HFCWO may help to reduce lung function decline, need for oral antibiotics, and reduced hospitalization rate.
Highlights
There is a paucity of data on long term clinical effects of high frequency chest wall oscillation (HFCWO) in the Bronchiectasis population
Several treatment options that have been applied to Bronchiectasis caused by Cystic Fibrosis (CF) have been applied to Bronchiectasis with moderate success
Patients were referred for advanced management of Bronchiectasis and were treated per the therapeutic algorithm if they reported greater than 2 exacerbations in the previous year and symptoms that warrant entry by the clinic staff
Summary
There is a paucity of data on long term clinical effects of high frequency chest wall oscillation (HFCWO) in the Bronchiectasis population Other therapies such as nebulized mucolytics and long term antibiotics have proven benefit on quality of life and exacerbation rate. Several treatment options that have been applied to Bronchiectasis caused by Cystic Fibrosis (CF) have been applied to Bronchiectasis with moderate success Inhaled antibiotics such as tobramycin and colistin have been studied with improved outcomes on preventing exacerbations and treating bacterial infections [3, 4]. Long-term oral therapy with erythromycin was shown to decrease the number of exacerbations in a 12-month span, and there remains concern about increased macrolide resistant in common pulmonary infections [5]. A greater understanding of therapies is needed to improve clinical outcomes for Bronchiectasis
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have